New monoclonal antibodies to oestrogen and progesterone receptors effective for paraffin section immunohistochemistry

Assessment of oestrogen and progesterone receptors (ER and PgR) in breast cancer is widely used for the prediction of response to endocrine therapy and as a prognostic marker. Cytosolic assays have been replaced in many centres by immunochemical techniques, which have many advantages including applicability to small samples, simplicity, and cost‐effectiveness. This study describes the generation and characterisation of two novel murine monoclonal antibodies recognizing ER and PgR, designated NCL‐ER‐6F11 and NCL‐PGR respectively, which are effective in heat‐treated formalin‐fixed, paraffin‐embedded tissue. The antibodies have been characterized by Western blotting and by immunohistochemistry on normal and pathological breast and other tissues. NCL‐ER‐6F11 has been shown to compare favourably with a currently available ER antibody. These antibodies may prove of value in the assessment of hormone receptor status in human breast cancer. © 1997 John Wiley & Sons, Ltd.

[1]  J. Meienhofer,et al.  Solid-phase peptide synthesis using mild base cleavage of N alpha-fluorenylmethyloxycarbonylamino acids, exemplified by a synthesis of dihydrosomatostatin. , 2009, International journal of peptide and protein research.

[2]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .

[3]  J. Feldman,et al.  Estrogen receptor immunocytochemistry in paraffin embedded tissues with ER1D5 predicts breast cancer endocrine response more accurately than H222Spγ in frozen sections or cytosol‐based ligand‐binding assays , 1996, Cancer.

[4]  S Detre,et al.  A "quickscore" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. , 1995, Journal of clinical pathology.

[5]  M. Dowsett,et al.  Comparison of new immunohistochemical assay for oestrogen receptor in paraffin wax embedded breast carcinoma tissue with quantitative enzyme immunoassay. , 1994, Journal of clinical pathology.

[6]  A. Bateman,et al.  immunocytochemistry: a study of 80 antibodies , 2022 .

[7]  J. Coindre,et al.  Production of monoclonal antibodies to human estrogen‐receptor protein (ER) using recombinant ER (RER) , 1993, International journal of cancer.

[8]  D. Potvin,et al.  Prognostic significance of cathepsin‐D expression in node‐positive breast carcinoma: An immunohistochemical study , 1993, International journal of cancer.

[9]  C. Elston,et al.  Methodology of immunohistological detection of oestrogen receptor in human breast carcinoma in formalin‐fixed, paraffin‐embedded tissue: a comparison with frozen section methodology , 1993, Histopathology.

[10]  S. Gebhard,et al.  Oestrogen receptor, progesterone receptor, pS2, ERD5, HSP27 and cathepsin D in invasive ductal breast carcinomas , 1993, Histopathology.

[11]  R. Coombes,et al.  Prediction of response to endocrine therapy in breast cancer using immunocytochemical assays for pS2, oestrogen receptor and progesterone receptor , 1993, International journal of cancer.

[12]  London.  Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: the Scottish trial , 1993 .

[13]  London Scottish Cancer Trials Breast Group And Icrf Breas GUY'S HOSPITAL.  Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: the Scottish trial , 1993, The Lancet.

[14]  P. Bell,et al.  Subintimal angioplasty for femoropopliteal artery occlusion , 1993, The Lancet.

[15]  Anthony Howell,et al.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. , 1992 .

[16]  M. Key,et al.  Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. , 1991, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[17]  N. Piggott,et al.  pNR-2/pS2 immunohistochemical staining in breast cancer: correlation with prognostic factors and endocrine response. , 1991, British Journal of Cancer.

[18]  S. Shousha,et al.  Demonstration of progesterone receptors in paraffin wax sections of breast carcinoma. , 1990, Journal of clinical pathology.

[19]  A. Leong,et al.  Oestrogen receptor staining of paraffin‐embedded breast carcinomas following short fixation in formalin: A comparison with cytosolic and frozen section receptor analyses , 1990, The Journal of pathology.

[20]  J. Cairns,et al.  Prognostic significance of the estrogen‐regulated protein, cathepsin D, in breast cancer. An immunohistochemical study , 1990, Cancer.

[21]  B. Angus,et al.  Oestrogen receptor and oestrogen regulated proteins in human breast cancer: a review. , 1989, The Keio journal of medicine.

[22]  U. Chetty,et al.  WHO NEEDS STEROID RECEPTOR ASSAYS? , 1989, The Lancet.

[23]  I. Fentiman,et al.  WHO NEEDS STEROID RECEPTOR ASSAYS? , 1989, The Lancet.

[24]  B. Asselain,et al.  Prognostic value of estrogen and progesterone receptors in operable breast cancer: Results of a univariate and multivariate analysis , 1988, Cancer.

[25]  M. Press,et al.  Progesterone receptor distribution in the human endometrium. Analysis using monoclonal antibodies to the human progesterone receptor. , 1988, The American journal of pathology.

[26]  T. Maudelonde,et al.  Immunoenzymatic assay of Mr 52,000 cathepsin D in 182 breast cancer cytosols: low correlation with other prognostic parameters. , 1988, Cancer research.

[27]  S. Thorpe.  Monoclonal antibody technique for detection of estrogen receptors in human breast cancer: greater sensitivity and more accurate classification of receptor status than the dextran-coated charcoal method. , 1987, Cancer research.

[28]  N. Keiding,et al.  Prognostic value of steroid hormone receptors: multivariate analysis of systemically untreated patients with node negative primary breast cancer. , 1987, Cancer research.

[29]  K. Rogers,et al.  Immunohistology of oestrogen receptor and D5 antigen in breast cancer: correlation with oestrogen receptor content of adjacent cryostat sections assayed by radioligand binding and enzyme immunoassay. , 1987, Journal of clinical pathology.

[30]  I. Ellis,et al.  Oestrogen receptors in primary and advanced breast cancer: an eight year review of 704 cases. , 1987, British Journal of Cancer.

[31]  K. Sangster,et al.  Histochemical detection of oestrogen receptors in breast carcinoma: a successful technique. , 1986, British Journal of Cancer.

[32]  A. Howell,et al.  STEROID-HORMONE RECEPTORS AND SURVIVAL AFTER FIRST RELAPSE IN BREAST CANCER , 1984, The Lancet.

[33]  W. McGuire,et al.  Progesterone receptors as a prognostic factor in stage II breast cancer. , 1983, The New England journal of medicine.

[34]  P. Mullins,et al.  Progesterone and estrogen receptors as prognostic variables in breast cancer. , 1983, Cancer research.

[35]  Richard A. Lerner,et al.  Immunogenic structure of the influenza virus hemagglutinin , 1982, Cell.

[36]  A. Forrest,et al.  Oestrogen receptors and breast cancer: Current status , 1980, British Journal of Surgery.

[37]  D. Katz,et al.  New procedures for preparation and isolation of conjugates of proteins and a synthetic copolymer of D-amino acids and immunochemical characterization of such conjugates. , 1979, Biochemistry.

[38]  W. McGuire,et al.  Estrogen control of progesterone receptor in human breast cancer: role of estradiol and antiestrogen. , 1978, Endocrinology.

[39]  W. McGuire,et al.  Estrogen control of progesterone receptor in human breast cancer. Correlation with nuclear processing of estrogen receptor. , 1978, The Journal of biological chemistry.

[40]  R. Peto,et al.  Smoking and cancer. , 1973, Lancet.

[41]  Braimbridge Mv.  HAEMOLYTIC ANAEMIA AND ACUTE RENAL DISEASE. , 1965 .

[42]  A. Hecht.  Progress in Pathology , 1948, Der Pathologe.

[43]  A. D. Schryver,et al.  Systemic treatment of early breast-cancer by hormonal, cytotoxic, or immune therapy: 133 randomized trials involving 31000 recurrences and 24000 deaths among 75000 women: 1 , 1992 .

[44]  N. Tallada,et al.  An Immunohistochemical Study , 1992 .

[45]  W. McGuire,et al.  The clinical usefulness of oestrogen-receptor and other markers of hormone dependence , 1989 .

[46]  Desombre Er.  Steroid receptors in breast cancer. , 1984, Monographs in pathology.